Long-Term Outcomes of Sotorasib Efficacy in Patients With KRASG12C Mutated NSCLC

Opinion
Video

CodeBreaK 100 compares the safety and efficacy of pembrolizumab combined with adagrasib or sotorasib in treating KRAS G12C NSCLC, noting sotorasib has a longer presence and familiarity in clinical use.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      Stage IV lung cancer may be curable based on the success of the DREAM Program, according to thoracic surgeon, Ankit Bharat, MBBS,
      Life-Saving Surgery in Lung Cancer May Be Uncovered Through Information-Seeking
      Ankit Bharat, MBBS, a thoracic surgeon, discussed potential treatment emergent adverse effects or complications, as well as strategies for managing them.
      Elucidating the Safety Profile of Double Lung Transplantation
      Thoracic surgeon, Ankit Bharat, MBBS, discussed surgical strategies among patients with advanced lung cancer diagnoses based on staging.
      Identifying the Treatment Landscape for Advanced Lung Cancers
      2 experts in this video
      COCOON in Practice: Patient Preparation, Key Insights, and Implementation Best Practices
      2 experts in this video
      Operational Considerations: Workflow Adjustments and Monitoring Systems for Effective COCOON Implementation
      2 experts in this video
      Building Support Systems: Resources and Multidisciplinary Collaboration for Optimizing COCOON Implementation
      2 experts in this video
      Measuring Impact: Observed Differences in Dermatologic AEs Between COCOON Protocol and Standard Approaches
      Treatment with lorlatinib might be effective regardless of the presence of central nervous system metastases, according to Misako Nagasaka, MD, PhD.
      Lorlatinib Yields Distinguishing CNS Benefit in ALK-Positive NSCLC
      Most central nervous system events with lorlatinib were grade 1 or 2 in the phase 3 CROWN trial.
      Mitigating CNS Events Is “Key” With Lorlatinib for ALK-Positive NSCLC
      Treatment with lorlatinib did not increase cardiovascular events among patients with ALK-positive non–small cell lung cancer in the CROWN trial.
      Lorlatinib Yields No Unexpected Toxicities in ALK-Positive NSCLC
      Related Content
      Data from the phase 3 GEMSTONE-302 trial support sugemalimab plus chemotherapy as a frontline treatment option in metastatic non–small cell lung cancer.

      Sugemalimab/Chemotherapy Improves Long-Term Survival in Metastatic NSCLC

      Russ Conroy
      June 20th 2025
      Article

      Data from the phase 3 GEMSTONE-302 trial support sugemalimab plus chemotherapy as a frontline treatment option in metastatic non–small cell lung cancer.

      Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

      Practice-Changing Lung Cancer Data From The 2025 ASCO Annual Meeting

      Stephen V. Liu, MD;Joshua K. Sabari, MD
      June 23rd 2025
      Podcast

      Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

      Sacituzumab tirumotecan showed a manageable safety profile compared to docetaxel in patients with EGFR-mutant advanced non–small cell lung cancer.

      Sacituzumab Tirumotecan Enhances Efficacy in Pretreated EGFR-Mutant NSCLC

      Roman Fabbricatore
      June 9th 2025
      Article

      Sacituzumab tirumotecan showed a manageable safety profile compared to docetaxel in patients with EGFR-mutant advanced non–small cell lung cancer.

      Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

      Adopting Best Practices for Administering TROP2-Directed ADCs in NSCLC

      Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
      June 16th 2025
      Podcast

      Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

      Among 44 patients with EGFR-positive non–small cell lung cancer who discontinued docetaxel, 36.4% crossed over to the sac-TMT arm.

      Sacituzumab Tirumotecan Improves Response vs Docetaxel in EFGR+ NSCLC

      Ashley Chan
      June 5th 2025
      Article

      Among 44 patients with EGFR-positive non–small cell lung cancer who discontinued docetaxel, 36.4% crossed over to the sac-TMT arm.

      The DREAM program led by Ankit Bharat, MD, MBBS, FACS, allowed Cornelia Tischmacher to receive a double lung transplant for her stage IV lung cancer.

      An International Search for Lung Cancer Treatment Leads to Double Lung Transplant

      Roman Fabbricatore
      June 4th 2025
      Article

      The DREAM program led by Ankit Bharat, MD, MBBS, FACS, allowed Cornelia Tischmacher to receive a double lung transplant for her stage IV lung cancer.